Ocular Therapeutix Inc. (OCUL)

Trade OCUL now with
7/17/2020 7:39:27 AM Ocular Therapeutix Projects Total Product Net Revenue Of $1.6 Million For June Quarter
5/20/2020 7:33:06 AM Ocular Therapeutix Prices Public Offering Of 8.18 Mln Shares At $5.50/Shr For Gross Proceeds Of $45 Mln
9/24/2019 8:18:08 AM Ocular Therapeutix Announces First Patient Dosed In Phase 3 Clinical Trial Of DEXTENZA For Allergic Conjunctivitis
7/26/2019 8:12:00 AM Ocular Therapeutix Announces Early Assignment Of Permanent And Specific J-Code For DEXTENZA 0.4mg By CMS
7/11/2019 4:04:18 PM Ocular Therapeutix Appoints Christopher White As SVP, Head Of Business And Corporate Development
7/9/2019 8:07:02 AM Ocular Therapeutix Announces Patricia Kitchen As Chief Operations Officer
1/7/2019 9:06:21 AM Purdue, Ocular Initiate Collaborative Research Activities To Evaluate Formulations For Non-Opioid Treatments For Pain
12/3/2018 7:16:11 AM Ocular Therapeutix: FDA Approve DEXTENZA 0.4mg For Treatment Of Ocular Pain Following Ophthalmic Surgery
10/19/2018 7:58:18 AM Ocular Therapeutix Receives FDA Warning Letter Related To ReSure Sealant
7/19/2018 8:08:28 AM Ocular Therapeutix Announces FDA Acceptance Of NDA Resubmission For DEXTENZA
6/29/2018 8:03:56 AM Ocular Therapeutix Announces NDA Resubmission Of DEXTENZA
5/3/2018 8:43:06 AM Ocular Announces Treatment Of 1st Patient In Phase 1 Trial Of OTX-TIC For Treatment Of Glaucoma And Ocular Hypertension
3/8/2018 7:33:10 AM Ocular Therapeutix Q4 Loss/shr $0.44 Vs. Loss/shr $0.52 Prior Year